Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.47 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | CBR1 | P16152 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1917291 | 0.90 | KDM1A (0.60) | GSK3BMEN1KMT2ACA12CA1 | |
| SCHEMBL1918574 | 0.90 | CA12 (0.49) | GSK3BMEN1KMT2ASYKCA12 | |
| SCHEMBL1918211 | 0.89 | SYK (0.56) | GSK3BSYKCA12CA1CA2 | |
| SCHEMBL1918062 | 0.88 | KDM1A (0.55) | GSK3BMEN1KMT2ACA12CA1 | |
| SCHEMBL1918691 | 0.84 | GSK3B (0.55) | GSK3BSYKPOLA1AKR1B10AKR1B1 | |
| SCHEMBL1918049 | 0.84 | MAPT (0.49) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL6081433 | 0.83 | KDM1A (0.51) | GSK3BMEN1KMT2ACA12CA1 | |
| SCHEMBL6080527 | 0.83 | CA1 (0.52) | GSK3BCA12CA1CA2CA9 | |
| SCHEMBL6080869 | 0.83 | POLB (0.55) | GSK3BMEN1KMT2ACA12CA1 | |
| SCHEMBL6081213 | 0.83 | MEN1 (0.48) | GSK3BMEN1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | SCRAS | 2006-10-19 | — | — | US | claimed |
| EP-1602368-A2 | Cdc25 phosphatase inhibitors | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2005-12-07 | — | — | EP | claimed |
| JP-2004506618-A | — | — | 2004-03-04 | — | — | JP | claimed |
| US-20040034103-A1 | Cdc25 photophatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-02-19 | — | — | US | claimed |
| CN-1474689-A | CDC25 phosphatase inhibitors | ��ѧ�о���Ӧ����ѯ��˾ | 2004-02-11 | — | — | CN | claimed |
| EP-1370255-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-12-17 | — | — | EP | claimed |
| WO-2002009686-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2002-02-07 | — | — | WO | claimed |
| EP-2335702-A1 | Product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent | IPSEN PHARMA (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFICQUES | 2009-10-08 | — | — | US | disclosed |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-05-28 | — | — | US | disclosed |
| EP-1792905-A1 | Product containing at least one phosphatase CDC25 inhibitor combined with at least one other anticancer agent | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2007-06-06 | — | — | EP | disclosed |
| US-7196084-B2 | Cdc25 phosphatase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-03-27 | — | — | US | disclosed |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2006-12-14 | — | — | US | disclosed |
| US-20060154933-A1 | Inhibitors of Cdc25 phosphatases | SCRAS | 2006-07-13 | — | — | US | disclosed |
| EP-1641453-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-04-05 | — | — | EP | disclosed |
| EP-1602368-A2 | Cdc25 phosphatase inhibitors | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005000852-A2 | PRODUCT CONTAINING AT LEAST ONE PHOSPHATASE CDC25 INHIBITOR COMBINED WITH AT LEAST ONE OTHER ANTICANCER AGENT | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2005-01-06 | — | — | WO | disclosed |
| US-20040034103-A1 | Cdc25 photophatase inhibitors | IPSEN PHARMA S.A.S. (FR) | 2004-02-19 | — | — | US | disclosed |
| EP-1370255-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002009686-A2 | CDC25 PHOSPHATASE INHIBITORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034103-A1 | Cdc25 photophatase inhibitors | CDC25C, CDC25A, CDC25B | GSK3B 620/4885MEN1 3563/4885KMT2A 2705/4885 |
| US-20090137596-A1 | G-PROTEIN INHIBITOR | CDC25A, CDC25C, CDC25B | GSK3B 1201/4885MEN1 1031/4885KMT2A 1598/4885 |
| US-20060154933-A1 | Inhibitors of Cdc25 phosphatases | CDC25A, CDC25C, CDC25B | GSK3B 491/4885MEN1 1858/4885KMT2A 1728/4885 |
| US-20060281736-A1 | Product comprising at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent | CDC25A, CDC25C, CDC25B | GSK3B 801/4885MEN1 982/4885KMT2A 1461/4885 |
| US-20060235027-A1 | Inhibitors of cdc25 phosphatases | CDC25A, CDC25C, CDC25B | GSK3B 491/4885MEN1 1858/4885KMT2A 1728/4885 |
| US-20090253685-A1 | Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent | CDC25A, CDC25C, CDC25B | GSK3B 730/4885MEN1 954/4885KMT2A 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.